NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT06704724 2026-03-13A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.PfizerPhase 1 Active not recruiting30 enrolled
NCT06447662 2026-02-25A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.PfizerPhase 1 Recruiting330 enrolled
NCT05544929 2026-01-06A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersNovartisPhase 1 Active not recruiting126 enrolled
NCT03785249 2025-09-30Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Mirati Therapeutics Inc.Phase 1/2 Active not recruiting731 enrolled 2 FDA
NCT04354246 2025-05-22COM902 (A TIGIT Inhibitor) in Subjects With Advanced MalignanciesCompugen LtdPhase 1 Active not recruiting110 enrolled
NCT05572684 2024-12-16A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid TumorsNextCure, Inc.Phase 1/2 Active not recruiting97 enrolled
NCT03621982 2024-06-13Study of ADCT-301 in Patients With Selected Advanced Solid TumorsADC Therapeutics S.A.Phase 1 Terminated78 enrolled 39 charts
NCT05708950 2023-07-13A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)Kineta Inc.Phase 1/2 Unknown314 enrolled